CNTB Connect Biopharma Holdings Limited Forecast, Technical & Fundamental Analysis
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD)... Show more
CNTB is expected to report earnings to fall 7.79% to -213 cents per share on September 15
Q2'26
Est.
$-2.13
Q1'26
Missed
by $2.07
Q4'25
Beat
by $1.84
Q3'25
Beat
by $1.80
Q2'25
Beat
by $1.73
The last earnings report on May 12 showed earnings per share of -230 cents, missing the estimate of -23 cents. With 2.49M shares outstanding, the current market capitalization sits at 154.89M.
A.I.dvisor indicates that over the last year, CNTB has been loosely correlated with AMRN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CNTB jumps, then AMRN could also see price increases.
CNTB in upward trend: price may jump up because it broke its lower Bollinger Band on June 02, 2026
CNTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where CNTB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 70 cases where CNTB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on CNTB as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CNTB just turned positive on June 24, 2026. Looking at past instances where CNTB's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNTB advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 50-day moving average for CNTB moved below the 200-day moving average on June 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNTB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CNTB entered a downward trend on July 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.939) is normal, around the industry mean (20.992). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CNTB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (476.190) is also within normal values, averaging (368.009).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
